The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Richard Schilsky to leave role as PI of ASCO’s TAPUR study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Richard L. Schilsky will be leaving his role as inaugural principal investigator of the American Society of Clinical Oncology-led Targeted Agent and Profiling Utilization Registry study after a decade of leadership.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Patricio Polanco named chief of surgical oncology and surgeon-in-chief at Atrium Health Levine Cancer

Patricio M. Polanco, a surgical oncologist specializing in hepato-pancreato-biliary malignancies and minimally invasive and robotic liver and pancreas surgery, has joined Atrium Health as division chief of surgical oncology, surgeon-in-chief for Atrium Health Levine Cancer in Charlotte, North Carolina and inaugural Richard L. White Jr. Endowed Professor of Surgery at Wake Forest University School of Medicine. 
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account